Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07618520 · ClinicalTrials.gov registry record · NA
Expanding Genetic Access for Prostate Cancer Survivors
A NA study, sponsored by Georgetown University.
- Not yet
- Registry status
- NA
- Development phase
- 500
- Enrollment target
NCT07618520: Clinical Trial NA study, sponsored by Georgetown University.
NCT07618520 is a NA study that has not yet begun recruiting, run by Georgetown University. The registered enrollment target is 500 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07618520, a NA study, has not yet begun recruiting, sponsored by Georgetown University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
Study Summary
The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will: Test the effectiveness of a digital guide (DG+) vs. print guide (Print+) vs. enhanced usual care (EUC) on engagement in genetic education and uptake of genetic testing. Evaluate the impact of the DG+ vs. Print+ vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes). Explore the ways (methods) that influence how participants experience the intervention. The main questions this study aims to answer are: which group - the digital guide (DG+) group, print (Print+) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education. Participants will be randomly assigned to either the digital guide (DG+) group, the print guide (Print+) group or EUC group. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the three groups to determine which is most most likely to complete genetic testing (GT) and which group engages more with genetic education.
Primary Outcome
As captured via internal RedCap form for the number or count of participants who opt for genetic testing during the six-month study period. The investigators will compare the three study arms to evaluate efficacy of the DG+ and Print+ interventions compared to EUC and to each other.
Interventions
- BEHAVIORAL Enhanced Usual Care
- BEHAVIORAL Print Genetic Education Guide
- BEHAVIORAL Digital Guide Genetic Education Guide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-07-31 |
| Phase | NA |
What is known before NCT07618520 opens enrollment
NCT07618520 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 3 interventions - of which Enhanced Usual Care is the first listed.
NCT07618520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07618520 about?
NCT07618520 is a clinical study titled "Expanding Genetic Access for Prostate Cancer Survivors". The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will: Test the effectiveness of a digital guide (DG+) vs. print guide (Print+) vs. enhanced usual care (EUC) on engagement in genetic education and uptak...
What is the current status of trial NCT07618520?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2026-08-01. Estimated completion is 2030-07-31.
What interventions are being tested in trial NCT07618520?
The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), Print Genetic Education Guide (BEHAVIORAL), Digital Guide Genetic Education Guide (BEHAVIORAL).
Who is sponsoring clinical trial NCT07618520?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07618520's enrollment target sits among peer trials
500 193rd of 2000 higher than 1,788 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI